Bridgefront Capital, LLC Uni Qure N.V. Transaction History

Bridgefront Capital, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.39 - $5.43 $44,611 - $55,179	-10,162 Reduced 42.91%	13,519 $60,000
Q1 2024 May 15, 2024	BUY	$4.82 - $6.93 $114,142 - $164,109	23,681 New	23,681 $123,000
Q3 2023 Nov 14, 2023	BUY	$6.71 - $11.83 $6,233 - $10,990	929 Added 8.39%	12,005 $80,000
Q2 2023 Aug 14, 2023	BUY	$11.12 - $22.2 $123,165 - $245,887	11,076 New	11,076 $126,000

154

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $813M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgefront Capital, LLC with notifications on news.